Intellia Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M | $58.0M | $43.1M | $30.4M |
| Cost of Revenue | — | — | — | — | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | $33.1M | $58.0M | $43.1M | $30.4M |
| Gross Margin | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Expenses | ||||||||
| Research & Development | $388.9M | $466.3M | $435.1M | $420.0M | $229.8M | $150.4M | $108.4M | $89.1M |
| SG&A Expense | $119.8M | $125.8M | $116.5M | $90.3M | $71.1M | $44.2M | $41.1M | $32.2M |
| Operating Income | $-441.0M | $-534.3M | $-515.3M | $-458.2M | $-267.9M | $-136.6M | $-106.4M | $-90.9M |
| Operating Margin | -651.7% | -923.1% | -1,420.5% | -879.0% | -810.4% | -235.5% | -246.8% | -298.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | — | — | — | — | — | — | — |
| Net Income | $-412.7M | $-519.0M | $-481.2M | $-474.2M | $-267.9M | $-134.2M | $-474.2M | $-85.3M |
| Net Margin | -609.9% | -896.8% | -1,326.5% | -909.8% | -810.5% | -231.5% | -1,100.1% | -280.4% |
| EPS (Basic) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | $-2.11 | $-1.98 |
| EPS (Diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 | $-2.40 | $-2.11 | $-1.98 |
| Shares Outstanding (Basic) | 108.4M | 98.8M | 88.8M | 77.0M | 70.9M | 56.0M | 50.2M | 45.2M |
| Shares Outstanding (Diluted) | 108.4M | 98.8M | 88.8M | 77.0M | 70.9M | 56.0M | 50.2M | 45.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |